News, talk and articles
The latest news from PTC
-
Improving the Transition from Pediatric to Adult Care in Duchenne
PTC research highlights opportunities to improve the transition experience for young adults living with Duchenne In 2023, PTC supported a research project conducted by a patient-focused consultancy Redline Strategic exploring the experience for teenagers, young adults and caregivers living with Duchenne muscular dystrophy (Duchenne) as they transition from pediatric care to adult care. The research… -
Raising Voices for Duchenne
World Duchenne Awareness Day is on Sept. 7. In honor of this year’s theme, “raise your voice for Duchenne”, we are highlighting remarkable individuals in the Duchenne community who are doing just that: using their voices to raise awareness of Duchenne, advocating for those living with the condition and inspiring the community to join them… -
Checking In with Emerging Leaders at PTC
The Emerging Leaders program (ELP) at PTC is a six-month, nomination based, global program that was created specifically for individuals at PTC who demonstrate the passion and traits to become successful future leaders. The program was developed with the goal of establishing a healthy range of diversity at the top as these emerging leaders advance.… -
Making Gender Equality a Reality at PTC: Advancing Women
At PTC, we advance women professionally by providing career growth and professional learning and development opportunities. All employees are encouraged to create individual development plans. These plans are realized through a variety of learning resources and workplace training programs that are offered to equip employees with new technical and behavioral skills. These programs cover leadership… -
Making Gender Equality a Reality at PTC: Empowering and Inspiring Women
Achieving gender equality has always been a business priority at PTC, which is why we are proud of our female representation across the organization. Today, women represent 51.9 percent of our workforce in the U.S.*, 36 percent at Board of Directors level and 40 percent at Executive Committee level**. Furthermore, we have 66 percent female… -
PTC UK: The Passion that Keeps Us Going
PTC UK was the first office to open in Europe and hire the first employees to serve our patients in the region. Today, 23 employees are based in the UK, leading regional and global functions. In the last 10 years, the PTC UK team have worked in partnership with the scientific and rare disease community… -
Investing in Employees’ Learning and Development
At PTC, we invest in our people and dedicate resources to development and learning, ensuring our employees are supported and empowered in their careers. Investing in our employees’ learning, skills and career development is integral to PTC’s success. We offer several resources to support our employees’ well‑being, learning and career development while providing growth opportunities.… -
Debunking Myths About PKU
In honor of International PKU Awareness Day, June 28, members of the community helped us to debunk common myths about PKU. Watch the video below to hear from PKU advocates, healthcare professionals, a person living with PKU and a caregiver as they share the facts: International PKU Awareness Day is a global day hosted by… -
PTC International Ireland: A Decade of Serving Patients Around the World
Since 2014, the PTC office in Ireland has been the company’s international headquarters and a regional hub. With nine departments and more than 50 employees*, the cross-functional teams facilitate supply of PTC’s medicines across 50+ geographies, manage global quality operations and global pharmacovigilance activities as well as commercial sales and finances for Europe, Middle East… -
PTC Celebrates 10 Years of Impact in Europe
It has been 10 years since PTC entered the European market with a mission to improve the lives of people living with rare diseases. In the past decade, we have pioneered transformative progress and created possibilities for the rare disease community across Europe. PTC was founded with the mission to leverage its novel drug discovery…